Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistantStaphylococcus aureus
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistantStaphylococcus aureus
Authors
Keywords
-
Journal
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Volume 41, Issue 6, Pages 437-443
Publisher
Wiley
Online
2013-12-17
DOI
10.1111/1440-1681.12195
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study
- (2013) Anouk E. Muller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia
- (2012) E. Boselli et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil
- (2010) J.L. Kuti et al. CLINICAL MICROBIOLOGY AND INFECTION
- Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis
- (2010) A. Mary Vilay et al. CRITICAL CARE MEDICINE
- The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistantStaphylococcus aureus: vancomycin and linezolid
- (2010) Gary E. Stein et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections
- (2009) H. Kimko et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health‐System Pharmacists, and the Society of Infectious Diseases Pharmacists
- (2009) Michael J. Rybak et al. CLINICAL INFECTIOUS DISEASES
- Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci
- (2009) Paul G. Ambrose et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment
- (2009) Thomas Marbury et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
- (2008) M. Rybak et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006
- (2008) G. G. Zhanel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections
- (2008) G. J. Noel et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetic and pharmacodynamic profile of ceftobiprole
- (2008) Thomas P. Lodise et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic
- (2008) James A. Dowell et al. JOURNAL OF CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More